Indications
As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).
Composition
- Active substance
- rimonabant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zimulti
- Active substance
- rimonabant
- ATC code
- A08AX01
- Therapeutic area
- Obesity
- Marketing authorisation holder
- sanofi-aventis
- Status
- Withdrawn
- EU authorisation